乳腺癌已成为全球最常见的癌症，人表皮生长因子受体2（HER2）阳性乳腺癌恶性程度较高，早期易复发和转移，总体预后较差。HER2阳性乳腺癌的治疗因靶向药物的不断问世而呈现更多可能，这类药物包括单克隆抗体（曲妥珠单抗、帕妥珠单抗）、酪氨酸激酶抑制剂（奈拉替尼、拉帕替尼、吡咯替尼、图卡替尼）、抗体药物偶联物（T-DM1、DS-8201）。对HER2阳性乳腺癌靶向治疗药物的最新临床试验结果进行综述，以期为该类乳腺癌的临床用药提供参考。

Breast cancer has become the most common cancer in the world. Among them, human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly malignant, easy to relapse and metastasize in the early stage and the overall prognosis is poor. With the advent of targeted drugs, more possibilities have been provided for the treatment of HER2-positive breast cancer. These drugs include monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (neratinib, lapatinib, pyrotinib and tucatinib), antibody drug conjugates (T-DM1, DS-8201). This article aims to review the latest clinical trial results of targeted therapy drugs for HER2-positive breast cancer, in order to provide a reference for future clinical medication.

R979.1;R984

国家自然基金青年科学基金资助项目（81302841）；辽宁省高等学校优秀人才支持计划资助项目（LJQ2014086）